Evidence map›Paper›PMID 27929442›Full record

ArticleMolecules (Basel, Switzerland)2016

Synthesis and Antitumor Activity of 5-Bromo-7-azaindolin-2-one Derivatives Containing a 2,4-Dimethyl-1H-pyrrole-3-carboxamide Moiety.

Jun Zhang, Weiyi Shen, Xiaoning Li, Yun Chai, Senjun Li, Kai Lv, Huiyuan Guo, Mingliang Liu

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun ZhangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. jun0215@126.com.
Weiyi ShenZhejiang Starry Pharmaceutical Co. Ltd., Xianju 317300, China. swy109@starrypharma.com.
Xiaoning LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. lxn18273645@163.com.
Yun ChaiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. yunchai18@126.com.
Senjun LiZhejiang Starry Pharmaceutical Co. Ltd., Xianju 317300, China. lisj0966@163.com.
Kai LvInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. lvkailk@hotmail.com.
Huiyuan GuoInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. imbhyguo@126.com.
Mingliang LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. lmllyx@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report herein the design and synthesis of a series of novel 5-bromo-7-azaindolin-2-one derivatives containing a 2,4-dimethyl-1

Indexed as

A549 CellsAntineoplastic AgentsAza CompoundsCell SurvivalDrug Screening Assays, AntitumorHep G2 CellsHumansIndolesPyrrolesSunitinibAntineoplastic AgentsAza CompoundsIndolesPyrrolesSunitinib5-bromo-7-azaindolin-2-onesantitumor activitysynthesis

Identifiers

PMID27929442
PMCPMC6274105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.